LMDX

LumiraDx Limited (LMDX) | Rumor.io

LumiraDx

LMDX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)0%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about LMDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% +0	0% 0

Jun 26

Roche now owns LumiraDX UK Ltd., which holds all of LumiraDx's intellectual property.
There are 56 patents attributable to entities with "LumiraDX" in their name, all of which are assigned to LumiraDX UK Ltd.
Roche's ownership of LumiraDX UK Ltd. and its subsidiaries, including SureSensors, confirms that Roche ultimately owns LumiraDx's intellectual property.

Generated by AI

Sentiment

Of the messages about LMDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0% 0	56.5% -11.23
Bearish	100%	100%	100% 0	43.5% +11.23

Bullish· Oct 28

*LumiraDx Limited ($LMDX) may be on the verge of a major breakthrough, with Roche potentially acquiring 100% of the shares and offering a cash payout to shareholders.*
*A deal between Roche and LumiraDx Limited has been struck, with shareholders likely to receive a cash payout in the spring of 2025, potentially with a value of around $8 per share.*
*Patience is key for $LMDX shareholders, as a compensation package from Roche is expected to be announced soon, with the possibility of double payments for shares held before February.*

Bearish· Feb 26

The company is facing potential bankruptcy and insolvency, with some users suggesting that the founders and executives are trying to cover up the issue.
There are concerns about the company's debt, with some users estimating that it is around $500 million, and that this debt may not be recoverable.
The company's control structure and ownership have been called into question, with some users suggesting that there may be a conflict of interest or that the company is being manipulated by external entities.

Generated by AI

Topics

Of the messages about LMDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	86.32%
Controversies	—	—	—	12.38%
Earnings	—	—	—	0.33%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0.98%

Announcements· Dec 29

Roche has entered into a definitive agreement to acquire LumiraDx's Point of Care technology for $295 million, with an additional payment of up to $55 million for reimbursement of amounts to fund the point of care diagnostics platform business.
The transaction is expected to close by mid-2024, and LumiraDx will use the sale proceeds to repay outstanding amounts under the Loan Agreement, with no distribution to the company or its shareholders.
Veronique Ameye, Chief Executive Officer of LumiraDx, stated that the agreement will enable the company to continue its important work and increase the reach of its innovative technology globally, providing fast and easy access to better diagnostic testing for patients.

Technical Analysis· Oct 25

$LMDX has broken above $0.2150, potentially leading to further price increases.
A key level to watch for $LMDX is $0.1904, which needs to be broken and held above for the stock to continue its upward trend.
The 30/50 moving average on a 30-minute chart has not yet crossed, suggesting that $LMDX is in a pre-run phase before a potential major price move.

Generated by AI

Community

Of the messages about LMDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	95.55%
Newcomers	0%	0%	0%	4.45%

Regulars· Jun 26

The regulars are focused on the ownership of LumiraDx's intellectual property (IP) and the relationship between LumiraDx UK Ltd. and Roche, with some participants claiming that Roche owns all of the IP.
There is a dispute over the assignment of patents, with one participant claiming that all patents assigned to LumiraDx are now controlled by Roche, while another participant challenges this claim and demands evidence.
The regulars are also discussing the lack of evidence from one side of the argument, with one participant suggesting that their opponent cannot provide a complete Schedule of Assigned Intellectual Property from the Roche Asset Purchase Agreement.

Newcomers· Feb 9

The company is being liquidated, and its shares were cancelled by court order in May 2023.
The former company has been dissolved, and its shares are worthless, as they represent a company that no longer exists.
The insolvency petition filed with the court in the Cayman Islands and the court order dissolving the company make it clear that the company is no longer in operation.

Generated by AI

Also Discussed

Investors talking about LMDX also mention

#	Name	Attention
1	Avalo Therapeutics, Inc.AVTX	0%new
2	Cardio Diagnostics Holdings, Inc.CDIO	0%0
3	Fti Consulting Inc.FCN	0%new
4	HeartSciences Inc.HSCS	0%0
5	Tempest Therapeutics Inc.TPST	0%+0
6	Nxu, Inc.NXU	0%new
7	Getaround, Inc.GETR	0%new
8	NIR - Near Intelligence, Inc.	——
9	Apollomics Inc.APLM	0%0
10	Naya Biosciences Inc.INVO	0%0

LumiraDx Limited

Location

Social

What share of all stock conversation is about LMDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% +0	0% 0

Jun 26

Roche now owns LumiraDX UK Ltd., which holds all of LumiraDx's intellectual property.
There are 56 patents attributable to entities with "LumiraDX" in their name, all of which are assigned to LumiraDX UK Ltd.
Roche's ownership of LumiraDX UK Ltd. and its subsidiaries, including SureSensors, confirms that Roche ultimately owns LumiraDx's intellectual property.

Generated by AI

Sentiment

Of the messages about LMDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0% 0	56.5% -11.23
Bearish	100%	100%	100% 0	43.5% +11.23

Bullish· Oct 28

*LumiraDx Limited ($LMDX) may be on the verge of a major breakthrough, with Roche potentially acquiring 100% of the shares and offering a cash payout to shareholders.*
*A deal between Roche and LumiraDx Limited has been struck, with shareholders likely to receive a cash payout in the spring of 2025, potentially with a value of around $8 per share.*
*Patience is key for $LMDX shareholders, as a compensation package from Roche is expected to be announced soon, with the possibility of double payments for shares held before February.*

Bearish· Feb 26

The company is facing potential bankruptcy and insolvency, with some users suggesting that the founders and executives are trying to cover up the issue.
There are concerns about the company's debt, with some users estimating that it is around $500 million, and that this debt may not be recoverable.
The company's control structure and ownership have been called into question, with some users suggesting that there may be a conflict of interest or that the company is being manipulated by external entities.

Generated by AI

Topics

Of the messages about LMDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	86.32%
Controversies	—	—	—	12.38%
Earnings	—	—	—	0.33%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0.98%

Announcements· Dec 29

Roche has entered into a definitive agreement to acquire LumiraDx's Point of Care technology for $295 million, with an additional payment of up to $55 million for reimbursement of amounts to fund the point of care diagnostics platform business.
The transaction is expected to close by mid-2024, and LumiraDx will use the sale proceeds to repay outstanding amounts under the Loan Agreement, with no distribution to the company or its shareholders.
Veronique Ameye, Chief Executive Officer of LumiraDx, stated that the agreement will enable the company to continue its important work and increase the reach of its innovative technology globally, providing fast and easy access to better diagnostic testing for patients.

Technical Analysis· Oct 25

$LMDX has broken above $0.2150, potentially leading to further price increases.
A key level to watch for $LMDX is $0.1904, which needs to be broken and held above for the stock to continue its upward trend.
The 30/50 moving average on a 30-minute chart has not yet crossed, suggesting that $LMDX is in a pre-run phase before a potential major price move.

Generated by AI

Community

Of the messages about LMDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	95.55%
Newcomers	0%	0%	0%	4.45%

Regulars· Jun 26

The regulars are focused on the ownership of LumiraDx's intellectual property (IP) and the relationship between LumiraDx UK Ltd. and Roche, with some participants claiming that Roche owns all of the IP.
There is a dispute over the assignment of patents, with one participant claiming that all patents assigned to LumiraDx are now controlled by Roche, while another participant challenges this claim and demands evidence.
The regulars are also discussing the lack of evidence from one side of the argument, with one participant suggesting that their opponent cannot provide a complete Schedule of Assigned Intellectual Property from the Roche Asset Purchase Agreement.

Newcomers· Feb 9

The company is being liquidated, and its shares were cancelled by court order in May 2023.
The former company has been dissolved, and its shares are worthless, as they represent a company that no longer exists.
The insolvency petition filed with the court in the Cayman Islands and the court order dissolving the company make it clear that the company is no longer in operation.

Generated by AI

LumiraDx

Social

Jun 26

Sentiment

Bullish· Oct 28

Bearish· Feb 26

Topics

Announcements· Dec 29

Technical Analysis· Oct 25

Community

Regulars· Jun 26

Newcomers· Feb 9

Also Discussed

LumiraDx Limited

Company Information

Location

Social

Jun 26

Sentiment

Bullish· Oct 28

Bearish· Feb 26

Topics

Announcements· Dec 29

Technical Analysis· Oct 25

Community

Regulars· Jun 26

Newcomers· Feb 9

Also Discussed